Jazz Pharmaceuticals (JAZZ) SVP Karen J. Wilson Sells 3,760 Shares of Stock
Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Karen J. Wilson sold 3,760 shares of the business’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $165.00, for a total transaction of $620,400.00. Following the completion of the transaction, the senior vice president now owns 15,811 shares in the company, valued at approximately $2,608,815. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NASDAQ:JAZZ opened at $162.86 on Wednesday. The company has a quick ratio of 2.88, a current ratio of 3.00 and a debt-to-equity ratio of 0.55. The stock has a market cap of $9.96 billion, a PE ratio of 17.04, a price-to-earnings-growth ratio of 0.85 and a beta of 0.97. Jazz Pharmaceuticals has a one year low of $162.78 and a one year high of $165.81.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the consensus estimate of $2.73 by ($0.15). The business had revenue of $436.40 million for the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. equities analysts predict that Jazz Pharmaceuticals will post 11.65 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on the stock. BidaskClub upgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Wells Fargo restated an “outperform” rating and issued a $182.00 target price (up previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Tuesday. ValuEngine upgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 11th. B. Riley upped their price objective on shares of Jazz Pharmaceuticals from $206.00 to $211.00 and gave the company a “buy” rating in a report on Thursday, May 10th. Finally, HC Wainwright set a $160.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, May 9th. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $181.60.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.